New hope for transplant patients whose bodies fight back

NCT ID NCT06824103

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing the drug ruxolitinib in Chinese adults and adolescents (aged 12+) who have chronic graft-versus-host disease (cGvHD) that does not improve with standard steroid treatment. The goal is to see if ruxolitinib can help control the disease and reduce symptoms. About 50 participants will take the drug for up to 3 years while researchers monitor their response and safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Hefei, Anhui, 230001, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Nanning, Guangxi, 530021, China
Novartis Investigative Site
RECRUITING

Guiyang, Guizhou, 550004, China
Novartis Investigative Site
RECRUITING

Shijiazhuang, Hebei, 050000, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450003, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430030, China
Novartis Investigative Site
RECRUITING

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site
RECRUITING

Nanchang, Jiangxi, 330006, China
Novartis Investigative Site
RECRUITING

Chengdu, Sichuan, 610041, China
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site
RECRUITING

Ningbo, Zhejiang, 315016, China
Novartis Investigative Site
RECRUITING

Wenzhou, Zhejiang, 325000, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beijing, 100070, China
Novartis Investigative Site
RECRUITING

Changsha, 410000, China
Novartis Investigative Site
RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Shanhecun, 065201, China

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VS. HOST DISEASE CORTICOSTEROID-REFRACTORY CHRONIC GRAFT VS. HOST DISEASE GRAFT VS HOST DISEASE